Heterologous vaccination (ChAdOx1 and BNT162b2) induces a better immune response against the omicron variant than homologous vaccination
Background: The ongoing COVID-19 pandemic has seen the emergence of numerous novel variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. In this study, we compared the efficacy of three different forms of immunization against the wild-type, delta, and omicron variants o...
Saved in:
Main Authors: | Jaeeun Yoo (Author), Younjeong Kim (Author), Yu mi Cha (Author), Jaewoong Lee (Author), Yeon Jeong Jeong (Author), Si-Hyun Kim (Author), Lisa L. Maragakis (Author), Seungok Lee (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2023-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety of heterologous ChAdOx1-S/BNT162b2 primary schedule versus homologous BNT162b2 vaccination: Insights from an Italian post-marketing study, 2021
by: Francesca Fortunato, et al.
Published: (2023) -
Adverse reactions and production of neutralizing anti-SARS-CoV-2 antibodies after ChAdOx1 COVID-19 vaccination: A cross-sectional study in a single center
by: Yeon Jeong Jeong, et al.
Published: (2022) -
Risk of venous thrombotic events and thrombocytopenia in sequential time periods after ChAdOx1 and BNT162b2 COVID-19 vaccines: A national cohort study in England
by: Nick J Andrews, et al.
Published: (2022) -
Immunogenicity of BNT162b2 as a first booster after a ChAdOx1 primary series in a Thai geriatric population living with frailty
by: Suvimol Niyomnaitham, et al.
Published: (2024) -
Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT162b2 and after booster vaccination with BNT162b2 or mRNA-1273: A population-based cohort study (COVIDENCE UK)
by: Giulia Vivaldi, et al.
Published: (2022)